Search

Your search keyword '"Laborde, L"' showing total 129 results
Start Over Author "Laborde, L"
129 results on '"Laborde, L"'

6. Developement of real time diagnostics and feedback algorithms for JET in view of the next step

Author

Murari, A., Joffrin, E., Felton, R., Mazon, D., Zabeo, L., Albanese, R., Arena, P., Ambrosino, G., Ariola, M., Barana, O., Bruno, M., Laborde, L., Moreau, D., Piccolo, F., Sartori, F., Crisanti, F., De La Luna, E., and Sanchez, J.

Subjects
Physics - Plasma Physics
Abstract

Real time control of many plasma parameters will be an essential aspect in the development of reliable high performance operation of Next Step Tokamaks. The main prerequisites for any feedback scheme are the precise real-time determination of the quantities to be controlled, requiring top quality and highly reliable diagnostics, and the availability of robust control algorithms. A new set of real time diagnostics was recently implemented on JET to prove the feasibility of determining, with high accuracy and time resolution, the most important plasma quantities. With regard to feedback algorithms, new model–based controllers were developed to allow a more robust control of several plasma parameters. Both diagnostics and algorithms were successfully used in several experiments, ranging from H-mode plasmas to configuration with ITBs. Since elaboration of computationally heavy measurements is often required, significant attention was devoted to non-algorithmic methods like Digital or Cellular Neural/Nonlinear Networks. The real time hardware and software adopted architectures are also described with particular attention to their relevance to ITER., Comment: 12th International Congress on Plasma Physics, 25-29 October 2004, Nice (France)

Published
2004
Full Text
View/download PDF

7. LBA8 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways

Author

Tomasini, P., Cropet, C., Jeanson, A., Pérol, M., Mazieres, J., Fontaine, C., Rabeau, A., Meurer, M., Greillier, L., Le Ray, M., Laborde, L., Cohen, A., Martin, V., Roumieux, M., Monville, F., Vivier, E., Perol, D., Chabaud, S., and Barlesi, F.

Published
2024
Full Text
View/download PDF

9. Turbulent reacting flows in hypersonic aerodynamics

Author

Laborde, L., Nguyen-Bui, T. H., Duffa, G., Caltagirone, J. P., Beig, R., editor, Ehlers, J., editor, Frisch, U., editor, Hepp, K., editor, Jaffe, R. L., editor, Kippenhahn, R., editor, Ojima, I., editor, Weidenmüller, H. A., editor, Wess, J., editor, Zittartz, J., editor, Beiglböck, W., editor, and Bruneau, Charles-Henri, editor

Published
1998
Full Text
View/download PDF

10. Real-world outcomes for patients with metastatic non-small cell lung cancer according to first-line treatment

Author

Belaroussi, Y., primary, Cousin, S., additional, Carton, M., additional, Lebitasy, M., additional, Laborde, L., additional, Laurent, C., additional, Filleron, T., additional, Fajole, G., additional, Dejean, V., additional, Parent, D., additional, Loeb, A., additional, Habet, T., additional, Chambon, A., additional, Desroys du Roure, V., additional, Faralli, H., additional, Lebouc, M., additional, Pallenchier, S., additional, Simon, G., additional, Martin, A., additional, and Mathoulin-Pélissier, S., additional

Published
2021
Full Text
View/download PDF

14. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

Author

Mavaddat, N., Antoniou, A.C., Mooij, T.M., Hooning, M.J., Heemskerk-Gerritsen, B.A., Nogues, C., Laborde, L., Breysse, E., Stoppa-Lyonnet, D., Gauthier-Villars, M., Buecher, B., Caron, O., Fourme-Mouret, E., Fricker, J.P., Lasset, C., Bonadona, V., Berthet, P., Faivre, L., Luporsi, E., Mari, V., Gladieff, L., Gesta, P., Sobol, H., Eisinger, F., Longy, M., Dugast, C., Colas, C., Coupier, I., Pujol, P., Corsini, C., Lortholary, A., Vennin, P., Adenis, C., Nguyen, T.D., Delnatte, C., Tinat, J., Tennevet, I., Limacher, J.M., Maugard, C., Bignon, Y.J., Demange, L., Penet, C., Dreyfus, H., Cohen-Haguenauer, O., Venat-Bouvet, L., Leroux, D., Zattara-Cannoni, H., Fert-Ferrer, S., Bera, O., Ellis, S., Barrowdale, D., Frost, D., Evans, D.G., Izatt, L., Adlard, J., Eeles, R., Brewer, C., Tischkowitz, M., Henderson, A., Cook, J., Eccles, D., Hogervorst, F.B.L., Collee, J.M., Asperen, C.J. van, Mensenkamp, A.R., Ausems, M.G.E.M., Meijers-Heijboer, H.E.J., Engelen, K. van, Blok, M.J., Oosterwijk, J.C., Verloop, J., Broek, E. van den, Mourits, M.J.E., Koppert, L.B., Hopper, J.L., John, E.M., Chung, W.K., Andrulis, I.L., Daly, M.B., Buys, S.S., Benitez, J., Caldes, T., Jakubowska, A., Simard, J., Singer, C.F., Tan, Y., Olah, E., Navratilova, M., Foretova, L., Gerdes, A.M., Roos-Blom, M.J., Leeuwen, F.E. van, Arver, B., Olsson, H., Schmutzler, R.K., Engel, C., Kast, K., Phillips, K.A., Terry, M.B., Milne, R.L., Goldgar, D.E., Rookus, M.A., Andrieu, N., Easton, D.F., GENEPSO, EMBRACE, HEBON, kConFab Investigators, IBCCS, kConFab, BCFR, University of Cambridge [UK] (CAM), Netherlands Cancer Institute (NKI), Antoni van Leeuwenhoek Hospital, Erasmus MC Cancer Institute, Rotterdam, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut Curie [Paris], Institut Gustave Roussy (IGR), Département de médecine oncologique [Gustave Roussy], Centre Hospitalier Georges Renon [Niort] (CH Georges Renon Niort), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Catherine-de-Sienne [Nantes] (CCS), Manchester University NHS Foundation Trust (MFT), Guy's & St Thomas' NHS Foundation Trust, Chapel Allerton Hospital, University of Leeds, Royal Marsden NHS Foundation Trust, Royal Devon & Exeter Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Sheffield Children's NHS Foundation Trust, Wessex clinical genetics service, Vrije Universiteit Amsterdam [Amsterdam] (VU), University Medical Center Groningen [Groningen] (UMCG), Department of Medical Genetics, University Medical Center [Utrecht], Centre for MEGA Epidemiology, The University of Melbourne, Victoria, Australia, Department of Epidemiology, Cancer Prevention Institute of California, Columbia University [New York], Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, University of Toronto-Cancer Care Ontario, Division of Population Science, Fox Chase Cancer Center, Department of Internal Medicine, Huntsman Cancer Institute, Departemento Genetica Humana, Centro Nacional Investigaciones Oncologicas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Department of Genetics and Pathology, International Hereditary Cancer Centre-Pomeranian Medical University [Szczecin] (PUM), Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec, Division of Special Gynecology, Medizinische Universität Wien = Medical University of Vienna-Department of OB/GYN, Medizinische Universität Wien = Medical University of Vienna, National Institute of Oncology, Masaryk Memorial Cancer Institute (MMCI), Masaryk University [Brno] (MUNI), Department of Clinical Genetics [Copenhagen], Rigshospitalet [Copenhagen], Copenhagen University Hospital-Copenhagen University Hospital, The Netherlands Cancer Institute [Amsterdam, The Netherlands], Radiumhemmet, Karolinska University Hospital [Stockholm], Department of Oncology, Lund University Hospital, Division of Molecular Gyneco-Oncology, Department of Gynaecology and Obstetrics, Clinical Center Un, Institute for Medical Informatics, Statistics and Epidemiology [Leipzig] (IMISE), Universität Leipzig [Leipzig], Department of Gynaecology and Obstetrics, University Hospital Carl Gustav Carus, Dept of Haematology and Medical Oncology, Peter MacCallum Cancer Center, Department of Epidemiology [Columbia University], Columbia University [New York]-Columbia Mailman School of Public Health, Cancer Epidemiology Centre, Cancer Council Victoria, International Agency for Cancer Research (IACR), Netherlands Cancer Institute, Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, Mines Paris - PSL (École nationale supérieure des mines de Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris sciences et lettres (PSL), Cancer Research U.K. Genetic Epidemiology Unit, Strangeways Research Laboratory, Andrieu, Nadine, Human genetics, Epidemiology and Data Science, Mavaddat, Nasim [0000-0003-0307-055X], Eeles, Ros [0000-0002-3698-6241], Engel, Christoph [0000-0002-7247-282X], Apollo - University of Cambridge Repository, Pomeranian Medical University-International Hereditary Cancer Centre, Masaryk Memorial Cancer Institute (RECAMO), Columbia Mailman School of Public Health-Columbia University [New York], Institut Curie [Paris]-MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Antoniou, Antonis [0000-0001-9223-3116], Tischkowitz, Marc [0000-0002-7880-0628], Easton, Douglas [0000-0003-2444-3247], Medical Oncology, Surgery, Cancer Research UK (Reino Unido), NIH - National Cancer Institute (NCI) (Estados Unidos), United States Department of Health and Human Services, Ministerio de Economía y Competitividad (España), Unión Europea. Comisión Europea. European Research Council (ERC), Norwegian EEA Financial Mechanism, Hungarian Scientific Research Fund (Hungría), Ministry of Education, Youth and Sports (República Checa), MH CZ -DRO (MMCI), National Health and Medical Research Council (Australia), Australian National Breast Cancer Foundation, Cancer Australia, ERA-NET TRANSAN JTC 2012 Cancer, Transcan grant, Biotechnology and Biological Sciences Research Council (Reino Unido), Pink Ribbons Project, Netherlands Organisation of Scientific Research, Dutch Cancer Society (Holanda), Instituto de Salud Carlos III, Deutsche Krebshilfe, National Institute for Health Research (Reino Unido), Unión Europea. Comisión Europea. 7 Programa Marco, Ministry of Economic Development, Innovation and Export Trade-grant, Canadian Institutes of Health Research, Cancer Research UK, NIH National Cancer Institute (NCI), United States Department of Health & Human Services National Institutes of Health (NIH) - USA, Ministerio de Economia y Competividad (MINECO), European Research Council (ERC), Hungarian Research Grants, MEYS -NPS I, National Health and Medical Research Council of Australia, BBMRI grant, Pink Ribbon grants, Netherlands Organisation of Scientific Research grant, KWF Kankerbestrijding, Instituto de Salud Carlos III - ISCIII, National Institute for Health Research (NIHR), European Union Seventh Framework Program (2007-2013), Canadian Institutes of Health Research (CIHR), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), United States of Department of Health & Human Services, European Research Council, APH - Quality of Care, APH - Methodology, Graduate School, ARD - Amsterdam Reproduction and Development, RS: GROW - R4 - Reproductive and Perinatal Medicine, and MUMC+: DA KG Lab Centraal Lab (9)

Subjects
endocrine system diseases, SURGERY, [SDV]Life Sciences [q-bio], [SDV.GEN] Life Sciences [q-bio]/Genetics, Cohort Studies, 0302 clinical medicine, BRCA2 Mutation, Breast cancer, Surgical oncology, Prospective Studies, Prospective cohort study, skin and connective tissue diseases, Salpingo-oophorectomy/methods, 0303 health sciences, Natural menopause, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], Obstetrics, BRCA1 Protein, Breast Neoplasms/epidemiology, Incidence (epidemiology), Incidence, WOMEN, ASSOCIATION, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, OVARIAN, BRCA2 Protein/genetics, 3. Good health, Menopause, Risk-reducing salpingo-oophorectomy, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, SURVIVAL, Female, Research Article, Cohort study, Adult, medicine.medical_specialty, Salpingo-oophorectomy, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics, lcsh:RC254-282, 03 medical and health sciences, breast cancer, SDG 3 - Good Health and Well-being, [SDV.CAN] Life Sciences [q-bio]/Cancer, medicine, Humans, METAANALYSIS, 030304 developmental biology, BRCA2 Protein, [SDV.GEN]Life Sciences [q-bio]/Genetics, business.industry, CONSORTIUM, risk-reducing salpingo-oophorectomy, International Agencies, medicine.disease, BRCA1, BRCA2, KCONFAB, REDUCTION, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, LINK, Mutation, BRCA1 Protein/genetics, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Risk Reduction Behavior
Abstract

The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO. The BCFR was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organisations imply endorsement by the US Government or the BCFR. CNIO was partially supported by the Spanish Ministry of Economy and Competitiveness (MINECO) SAF2014-57680-R and the Spanish Research Network on Rare Diseases (CIBERER). CNIO was also partially supported by FISPI16/00440. INHERIT was supported by the Canadian Institutes of Health Research for the 'CIHR Team in Familial Risks of Breast Cancer' program-grant #CRN-87521-and the Ministry of Economic Development, Innovation and Export Trade-grant #PSR-SIIRI-701. The PERSPECTIVE project was supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (GPH-129344), the Ministere de l'Economie, de la Science et de l' Innovation du Quebec through Genome Quebec, and The Quebec Breast Cancer Foundation. Jacques Simard is a Chairholder of the Canada Research Chair in Oncogenetics. EMBRACE is supported by the Cancer Research UK grants C1287/A23382 and C1287/A16563. D. Gareth Evans is supported by an NIHR grant to the Biomedical Research Centre, Manchester (IS-BRC-1215-20007). The investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Ros Eeles and Elizabeth Bancroft are supported by the Cancer Research UK grant C5047/A8385. Ros Eeles is also supported by NIHR support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Antonis C. Antoniou is funded by Cancer Research UK grants C12292/A20861 and C12292/A11174. MT is funded by the European Union Seventh Framework Program (2007-2013)/European Research Council (310018). The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant no 110837, Rita K. Schmutzler). The national French cohort, GENEPSO, had been supported by a grant from the Fondation de France and the Ligue Nationale Contre le Cancer and is being supported by a grant from INCa as part of the European program ERA-NET on Translational Cancer Research (TRANSCAN-JTC2012, no. 2014-008). HCSC was supported by CIBERONC 161200301 from ISCIII (Spain), partially supported by European Regional Development FEDER funds. The HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the Netherlands Organisation of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187.WO76, the BBMRI grant NWO 184.021.007/CP46, and the Transcan grant JTC 2012 Cancer 12-054. The IHCC was supported by Grant PBZ_ KBN_122/P05/2004 and ERA-NET TRANSAN JTC 2012 Cancer 12-054 (ERA-NET-TRANSCAN/07/2014). This work was supported by grants to kConFab and the kConFab Follow-Up Study from Cancer Australia (809195); the Australian National Breast Cancer Foundation (IF 17); the National Health and Medical Research Council (454508, 288704, 145684); the National Institute of Health U.S.A. (1RO1CA159868); the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia; and the Cancer Foundation of Western Australia. KAP is an Australian National Breast Cancer Foundation fellow. MODSQUAD-Czech Republic, Brno, was supported by MH CZ -DRO (MMCI, 00209805) and by MEYS -NPS I -LO1413 to LF and MN. The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745, NKFI OTKA K-112228, and the Norwegian EEA Financial Mechanism HU0115/NA/2008-3/OP-9. Lund-BRCA collaborators are supported by the Swedish Cancer Society, Lund Hospital Funds, and European Research Council Advanced Grant ERC-2011-294576. Stockholm-BRCA collaborators are supported by the Swedish Cancer Society. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. Sí

Published
2020
Full Text
View/download PDF

15. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers.

Author

Bera O., Fourme-Mouret E., Fricker J.-P., Lasset C., Bonadona V., Berthet P., Faivre L., Luporsi E., Mari V., Gladieff L., Sobol H., Eisinger F., Longy M., Dugast C., Colas C., Coupier I., Corsini C., Vennin P., Adenis C., Nguyen T.D., Delnatte C., Tinat J., Tennevet I., Limacher J.-M., Maugard C., Bignon Y.-J., Demange L., Penet C., Cohen-Haguenauer O., Venat-Bouvet L., Leroux D., Dreyfus H., Zattara-Cannoni H., Fert-Ferrer S., Nogues C., Gauthier-Villars M., Caron O., Gesta P., Pujol P., Lortholary A., Ellis S., Barrowdale D., Frost D., Evans D.G., Izatt L., Adlard J., Eeles R., Brewer C., Tischkowitz M., Henderson A., Cook J., Eccles D., Hogervorst F.B.L., Collee J.M., Van Asperen C.J., Mensenkamp A.R., Meijers-Heijboer H.E.J., Blok M.J., Oosterwijk J.C., Verloop J., Van Den Broek E., Van Engelen K., Mourits M.J.E., Ausems M.G.E.M., Koppert L.B., Hopper J.L., John E.M., Chung W.K., Andrulis I.L., Daly M.B., Buys S.S., Benitez J., Caldes T., Jakubowska A., Simard J., Singer C.F., Tan Y., Olah E., Navratilova M., Foretova L., Gerdes A.-M., Roos-Blom M.-J., Van Leeuwen F.E., Arver B., Olsson H., Schmutzler R.K., Engel C., Kast K., Phillips K.-A., Terry M.B., Milne R.L., Goldgar D.E., Rookus M.A., Andrieu N., Easton D.F., Mavaddat N., Antoniou A.C., Mooij T.M., Hooning M.J., Heemskerk-Gerritsen B.A., Laborde L., Breysse E., Stoppa-Lyonnet D., Buecher B., Bera O., Fourme-Mouret E., Fricker J.-P., Lasset C., Bonadona V., Berthet P., Faivre L., Luporsi E., Mari V., Gladieff L., Sobol H., Eisinger F., Longy M., Dugast C., Colas C., Coupier I., Corsini C., Vennin P., Adenis C., Nguyen T.D., Delnatte C., Tinat J., Tennevet I., Limacher J.-M., Maugard C., Bignon Y.-J., Demange L., Penet C., Cohen-Haguenauer O., Venat-Bouvet L., Leroux D., Dreyfus H., Zattara-Cannoni H., Fert-Ferrer S., Nogues C., Gauthier-Villars M., Caron O., Gesta P., Pujol P., Lortholary A., Ellis S., Barrowdale D., Frost D., Evans D.G., Izatt L., Adlard J., Eeles R., Brewer C., Tischkowitz M., Henderson A., Cook J., Eccles D., Hogervorst F.B.L., Collee J.M., Van Asperen C.J., Mensenkamp A.R., Meijers-Heijboer H.E.J., Blok M.J., Oosterwijk J.C., Verloop J., Van Den Broek E., Van Engelen K., Mourits M.J.E., Ausems M.G.E.M., Koppert L.B., Hopper J.L., John E.M., Chung W.K., Andrulis I.L., Daly M.B., Buys S.S., Benitez J., Caldes T., Jakubowska A., Simard J., Singer C.F., Tan Y., Olah E., Navratilova M., Foretova L., Gerdes A.-M., Roos-Blom M.-J., Van Leeuwen F.E., Arver B., Olsson H., Schmutzler R.K., Engel C., Kast K., Phillips K.-A., Terry M.B., Milne R.L., Goldgar D.E., Rookus M.A., Andrieu N., Easton D.F., Mavaddat N., Antoniou A.C., Mooij T.M., Hooning M.J., Heemskerk-Gerritsen B.A., Laborde L., Breysse E., Stoppa-Lyonnet D., and Buecher B.

Abstract

Background: The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. Method(s): A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. Result(s): There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. Conclusion(s): We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.Copyright © 2020 The Author(s).

Published
2020

16. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

Author

Mavaddat, N, Antoniou, AC, Mooij, TM, Hooning, MJ, Heemskerk-Gerritsen, BA, Nogues, C, Laborde, L, Breysse, E, Stoppa-Lyonnet, D, Gauthier-Villars, M, Buecher, B, Caron, O, Fourme-Mouret, E, Fricker, J-P, Lasset, C, Bonadona, V, Berthet, P, Faivre, L, Luporsi, E, Mari, V, Gladieff, L, Gesta, P, Sobol, H, Eisinger, F, Longy, M, Dugast, C, Colas, C, Coupier, I, Pujol, P, Corsini, C, Lortholary, A, Vennin, P, Adenis, C, Nguyen, TD, Delnatte, C, Tinat, J, Tennevet, I, Limacher, J-M, Maugard, C, Bignon, Y-J, Demange, L, Penet, C, Dreyfus, H, Cohen-Haguenauer, O, Venat-Bouvet, L, Leroux, D, Zattara-Cannoni, H, Fert-Ferrer, S, Bera, O, Ellis, S, Barrowdale, D, Frost, D, Evans, DG, Izatt, L, Adlard, J, Eeles, R, Brewer, C, Tischkowitz, M, Henderson, A, Cook, J, Eccles, D, Hogervorst, FBL, Collee, JM, van Asperen, CJ, Mensenkamp, AR, Ausems, MGEM, Meijers-Heijboer, HEJ, van Engelen, K, Blok, MJ, Oosterwijk, JC, Verloop, J, van den Broek, E, Mourits, MJE, Koppert, LB, Hopper, JL, John, EM, Chung, WK, Andrulis, IL, Daly, MB, Buys, SS, Benitez, J, Caldes, T, Jakubowska, A, Simard, J, Singer, CF, Tan, Y, Olah, E, Navratilova, M, Foretova, L, Gerdes, A-M, Roos-Blom, M-J, Van Leeuwen, FE, Arver, B, Olsson, H, Schmutzler, RK, Engel, C, Kast, K, Phillips, K-A, Terry, MB, Milne, RL, Goldgar, DE, Rookus, MA, Andrieu, N, Easton, DF, Mavaddat, N, Antoniou, AC, Mooij, TM, Hooning, MJ, Heemskerk-Gerritsen, BA, Nogues, C, Laborde, L, Breysse, E, Stoppa-Lyonnet, D, Gauthier-Villars, M, Buecher, B, Caron, O, Fourme-Mouret, E, Fricker, J-P, Lasset, C, Bonadona, V, Berthet, P, Faivre, L, Luporsi, E, Mari, V, Gladieff, L, Gesta, P, Sobol, H, Eisinger, F, Longy, M, Dugast, C, Colas, C, Coupier, I, Pujol, P, Corsini, C, Lortholary, A, Vennin, P, Adenis, C, Nguyen, TD, Delnatte, C, Tinat, J, Tennevet, I, Limacher, J-M, Maugard, C, Bignon, Y-J, Demange, L, Penet, C, Dreyfus, H, Cohen-Haguenauer, O, Venat-Bouvet, L, Leroux, D, Zattara-Cannoni, H, Fert-Ferrer, S, Bera, O, Ellis, S, Barrowdale, D, Frost, D, Evans, DG, Izatt, L, Adlard, J, Eeles, R, Brewer, C, Tischkowitz, M, Henderson, A, Cook, J, Eccles, D, Hogervorst, FBL, Collee, JM, van Asperen, CJ, Mensenkamp, AR, Ausems, MGEM, Meijers-Heijboer, HEJ, van Engelen, K, Blok, MJ, Oosterwijk, JC, Verloop, J, van den Broek, E, Mourits, MJE, Koppert, LB, Hopper, JL, John, EM, Chung, WK, Andrulis, IL, Daly, MB, Buys, SS, Benitez, J, Caldes, T, Jakubowska, A, Simard, J, Singer, CF, Tan, Y, Olah, E, Navratilova, M, Foretova, L, Gerdes, A-M, Roos-Blom, M-J, Van Leeuwen, FE, Arver, B, Olsson, H, Schmutzler, RK, Engel, C, Kast, K, Phillips, K-A, Terry, MB, Milne, RL, Goldgar, DE, Rookus, MA, Andrieu, N, and Easton, DF

Abstract

BACKGROUND: The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. METHODS: A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. RESULTS: There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. CONCLUSION: We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.

Published
2020

18. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

Author

Terry, M-B. (Mary-beth), Liao, Y.Y., Kast, K. (Karin), Antoniou, A.C. (Antonis), McDonald, JA, Mooij, T.M. (Thea), Engel, C., Nogues, C. (Catherine), Buecher, B. (Bruno), Mari, V., Moretta-Serra, J., Gladieff, L, Luporsi, E., Barrowdale, D. (Daniel), Frost, D. (Debra), Henderson, A, Brewer, C. (C.), Evans, DGR, Eccles, D. (Diana), Cook, J. (Jackie), Ong, K.-R. (Kai-Ren), Izatt, L. (Louise), Ahmed, M., Morrison, P.J. (Patrick), Dommering, C.J. (Charlotte), Oosterwijk, J.C. (Jan), Ausems, M.G.E.M. (Margreet), Kriege, M., Buys, S.S. (Saundra), Andrulis, I.L. (Irene), John, E.M. (Esther), Daly, M.J. (Mark), Friedlander, M. (Michael), McLachlan, SA, Osorio, A. (Ana), Caldes, T. (Trinidad), Jakubowska, A. (Anna), Simard, J. (Jacques), Singer, C.F. (Christian), Tan, Y.H. (Yao Hua), Olah, E., Navratilova, M, Foretova, L. (Lenka), Gerdes, A-M. (Anne-Marie), Roos-Blom, M.J., Arver, B. (Brita Wasteson), Olsson, H. (Hans), Schmutzler, R.K. (Rita), Hopper, J. (John), Leeuwen, F.E. (Flora) van, Goldgar, D. (David), Milne, R.L. (Roger), Easton, D.F. (Douglas), Rookus, M.A. (M.), Andrieu, N, Evans, D.G. (Gareth), Adlard, J.W. (Julian), Eeles, R. (Rosalind), Davidson, R. (Rosemarie), Tischkowitz, M. (Marc), Snape, K., Walker, L.J. (Lisa), Porteous, M.E. (Mary), Donaldson, A. (Alan), Morrison, P, Eason, J. (Jacqueline), Rogers, M, Miller, C, Brady, A, Kennedy, M.J. (John), Barwell, J. (Julian), Gregory, H. (Helen), Pottinger, C. (Caroline), Murray, A. (Anna), Angelakos, M., Dite, G., Tsimiklis, H. (Helen), Breysse, E., Pontois, P., Laborde, L., Stoppa-Lyonnet, D. (Dominique), Gauthier-Villars, M. (Marion), Caron, O. (Olivier), Fourme-Mouret, E., Fricker, J.P. (Jean Pierre), Lasset, C. (Christine), Bonadona, V. (Valérie), Fert-Ferrer, S. (Sandra), Berthet, P. (Pascaline), Vénat-Bouvet, L. (Laurence), Gilbert-Dussardier, B., Faivre, L. (Laurence), Gesta, P., Sobol, H. (Hagay), Eisinger, F. (François), Longy, M. (Michel), Dugast, C., Coupier, I. (Isabelle), Colas, C. (Chrystelle), Soubrier, F., Pujol, P. (Pascal), Corsini, C., Lortholary, A, Vennin, P. (Philippe), Adenis, C., Nguyen, T.D., Penet, C., Delnatte, C.D. (Capucine), Tinat, J., Tennevet, I., Limacher, J.M., Maugard, C., Demange, L., Dreyfus, H. (Hélène), Cohen-Haguenauer, O. (Odile), Leroux, D. (Dominique), Zattara-Cannoni, H., Bera, O., Hogervorst, F.B.L. (Frans), Adank, M.A. (Muriel), Schmidt, M.K. (Marjanka), Russell, N.S. (Nicola), Jenner, D.J., Collée, J.M. (Margriet), Ouweland, A.M.W. (Ans) van den, Hooning, M.J. (Maartje), Seynaeve, C.M. (Caroline), Deurzen, C.H.M. (Carolien) van, Obdeijn, A.I.M. (Inge-Marie), Asperen, C.J. (Christi) van, Devilee, P. (P.), Kets, C.M. (Marleen), Mensenkamp, A.R. (Arjen), Koudijs, MJ, Aalfs, C.M. (Cora), Engelen, K. (Klaartje) van, Gille, J.J. (Johan), Gómez García, E.B. (Encarna), Blok, M.J.C., Hout, A.H. (Annemarie) van der, Mourits, M.J. (Marjan), Bock, G.H. (Geertruida) de, Siesling, S. (Sabine), Verloop, H. (Herman), Belt-Dusebout, A.W. (Alexandra) van den, Terry, M-B. (Mary-beth), Liao, Y.Y., Kast, K. (Karin), Antoniou, A.C. (Antonis), McDonald, JA, Mooij, T.M. (Thea), Engel, C., Nogues, C. (Catherine), Buecher, B. (Bruno), Mari, V., Moretta-Serra, J., Gladieff, L, Luporsi, E., Barrowdale, D. (Daniel), Frost, D. (Debra), Henderson, A, Brewer, C. (C.), Evans, DGR, Eccles, D. (Diana), Cook, J. (Jackie), Ong, K.-R. (Kai-Ren), Izatt, L. (Louise), Ahmed, M., Morrison, P.J. (Patrick), Dommering, C.J. (Charlotte), Oosterwijk, J.C. (Jan), Ausems, M.G.E.M. (Margreet), Kriege, M., Buys, S.S. (Saundra), Andrulis, I.L. (Irene), John, E.M. (Esther), Daly, M.J. (Mark), Friedlander, M. (Michael), McLachlan, SA, Osorio, A. (Ana), Caldes, T. (Trinidad), Jakubowska, A. (Anna), Simard, J. (Jacques), Singer, C.F. (Christian), Tan, Y.H. (Yao Hua), Olah, E., Navratilova, M, Foretova, L. (Lenka), Gerdes, A-M. (Anne-Marie), Roos-Blom, M.J., Arver, B. (Brita Wasteson), Olsson, H. (Hans), Schmutzler, R.K. (Rita), Hopper, J. (John), Leeuwen, F.E. (Flora) van, Goldgar, D. (David), Milne, R.L. (Roger), Easton, D.F. (Douglas), Rookus, M.A. (M.), Andrieu, N, Evans, D.G. (Gareth), Adlard, J.W. (Julian), Eeles, R. (Rosalind), Davidson, R. (Rosemarie), Tischkowitz, M. (Marc), Snape, K., Walker, L.J. (Lisa), Porteous, M.E. (Mary), Donaldson, A. (Alan), Morrison, P, Eason, J. (Jacqueline), Rogers, M, Miller, C, Brady, A, Kennedy, M.J. (John), Barwell, J. (Julian), Gregory, H. (Helen), Pottinger, C. (Caroline), Murray, A. (Anna), Angelakos, M., Dite, G., Tsimiklis, H. (Helen), Breysse, E., Pontois, P., Laborde, L., Stoppa-Lyonnet, D. (Dominique), Gauthier-Villars, M. (Marion), Caron, O. (Olivier), Fourme-Mouret, E., Fricker, J.P. (Jean Pierre), Lasset, C. (Christine), Bonadona, V. (Valérie), Fert-Ferrer, S. (Sandra), Berthet, P. (Pascaline), Vénat-Bouvet, L. (Laurence), Gilbert-Dussardier, B., Faivre, L. (Laurence), Gesta, P., Sobol, H. (Hagay), Eisinger, F. (François), Longy, M. (Michel), Dugast, C., Coupier, I. (Isabelle), Colas, C. (Chrystelle), Soubrier, F., Pujol, P. (Pascal), Corsini, C., Lortholary, A, Vennin, P. (Philippe), Adenis, C., Nguyen, T.D., Penet, C., Delnatte, C.D. (Capucine), Tinat, J., Tennevet, I., Limacher, J.M., Maugard, C., Demange, L., Dreyfus, H. (Hélène), Cohen-Haguenauer, O. (Odile), Leroux, D. (Dominique), Zattara-Cannoni, H., Bera, O., Hogervorst, F.B.L. (Frans), Adank, M.A. (Muriel), Schmidt, M.K. (Marjanka), Russell, N.S. (Nicola), Jenner, D.J., Collée, J.M. (Margriet), Ouweland, A.M.W. (Ans) van den, Hooning, M.J. (Maartje), Seynaeve, C.M. (Caroline), Deurzen, C.H.M. (Carolien) van, Obdeijn, A.I.M. (Inge-Marie), Asperen, C.J. (Christi) van, Devilee, P. (P.), Kets, C.M. (Marleen), Mensenkamp, A.R. (Arjen), Koudijs, MJ, Aalfs, C.M. (Cora), Engelen, K. (Klaartje) van, Gille, J.J. (Johan), Gómez García, E.B. (Encarna), Blok, M.J.C., Hout, A.H. (Annemarie) van der, Mourits, M.J. (Marjan), Bock, G.H. (Geertruida) de, Siesling, S. (Sabine), Verloop, H. (Herman), and Belt-Dusebout, A.W. (Alexandra) van den

Abstract

Background: Full-term pregnancy (FTP) is associated with a reduced breast cancer (BC) risk over time, but women are at increased BC risk in the immediate years following an FTP. No large prospective studies, however, have examined whether the number and timing of pregnancies are associated with BC risk for BRCA1 and BRCA2 mutation carriers. Methods: Using weighted and time-varying Cox proportional hazards models, we investigated whether reproductive events are associated with BC risk for mutation carriers using a retrospective cohort (5707 BRCA1 and 3525 BRCA2 mutation carriers) and a prospective cohort (2276 BRCA1 and 1610 BRCA2 mutation carriers), separately for each cohort and the combined prospective and retrospective cohort. Results: For BRCA1 mutation carriers, there was no overall association with parity compared with nulliparity (combined hazard ratio [HRc] ¼ 0.99, 95% confidence interval [CI] ¼ 0.83 to 1.18). Relative to being uniparous, an increased number of FTPs was associated with decreased BC risk (HRc¼ 0.79, 95% CI ¼ 0.69 to 0.91; HRc¼ 0.70, 95% CI ¼ 0.59 to 0.82; HRc¼ 0.50, 95% CI ¼ 0.40 to 0.63, for 2, 3, and 4 FTPs, respectively, Ptrend < .0001) and increasing duration of breastfeeding was associated with decreased BC risk (combined cohort Ptrend ¼ .0003). Relative to being nulliparous, uniparous BRCA1 mutation carriers were at increased BC risk in the prospective analysis (prospective hazard ration [HRp] ¼ 1.69, 95% CI ¼ 1.09 to 2.62). For BRCA2 mutation carriers, being parous was associated with a 30% increase in BC risk (HRc ¼ 1.33, 95% CI ¼ 1.05 to 1.69), and there was no apparent decrease in risk associated with multiparity except for having at least 4 FTPs vs. 1 FTP (HRc¼ 0.72, 95% CI ¼ 0.54 to 0.98). Conclusions: These findings suggest differential associations with parity between BRCA1 and BRCA2 mutation carriers with higher risk for uniparous BRCA1 carriers and parous BRCA2 carriers.

Published
2019

19. Oral contraceptive use and breast cancer risk: Retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study.

Author

Roos-Blom M.-J., Walker L., Bonadona V., Leroux D., Mouret-Fourme E., Venat-Bouvet L., Buys S.S., Southey M.C., John E.M., Chung W.K., Daly M.B., Bane A., van Asperen C.J., Garcia E.B.G., Mourits M.J., Friedlander M.L., McLachlan S.-A., Singer C.F., Foretova L., Gerdes A.-M., Caldes T., Olah E., Jakubowska A., Nogues C., Andrieu N., Easton D.F., van Leeuwen F.E., Hopper J.L., Milne R.L., Antoniou A.C., Rookus M.A., Laborde L., Pontois P., Stoppa-Lyonnet D., Gauthier-Villars M., Buecher B., Caron O., Fricker J.-P., Lasset C., Berthet P., Faivre L., Luporsi E., Frenay M., Gladieff L., Gesta P., Sobol H., Eisinger F., Moretta J., Longy M., Dugast C., Colas C., Soubrier F., Coupier I., Pujol P., Lortholary A., Vennin P., Adenis C., Nguyen T.D., Delnatte C., Rossi A., Tinat J., Tennevet I., Limacher J.-M., Maugard C., Bignon Y.-J., Demange L., Dreyfus H., Cohen-Haguenauer O., Gilbert B., Zattara-Cannoni H., Schrijver L.H., Olsson H., Phillips K.-A., Terry M.B., Goldgar D.E., Kast K., Engel C., Mooij T.M., Adlard J., Barrowdale D., Davidson R., Eeles R., Ellis S., Evans D.G., Frost D., Izatt L., Porteous M.E., Side L.E., Roos-Blom M.-J., Walker L., Bonadona V., Leroux D., Mouret-Fourme E., Venat-Bouvet L., Buys S.S., Southey M.C., John E.M., Chung W.K., Daly M.B., Bane A., van Asperen C.J., Garcia E.B.G., Mourits M.J., Friedlander M.L., McLachlan S.-A., Singer C.F., Foretova L., Gerdes A.-M., Caldes T., Olah E., Jakubowska A., Nogues C., Andrieu N., Easton D.F., van Leeuwen F.E., Hopper J.L., Milne R.L., Antoniou A.C., Rookus M.A., Laborde L., Pontois P., Stoppa-Lyonnet D., Gauthier-Villars M., Buecher B., Caron O., Fricker J.-P., Lasset C., Berthet P., Faivre L., Luporsi E., Frenay M., Gladieff L., Gesta P., Sobol H., Eisinger F., Moretta J., Longy M., Dugast C., Colas C., Soubrier F., Coupier I., Pujol P., Lortholary A., Vennin P., Adenis C., Nguyen T.D., Delnatte C., Rossi A., Tinat J., Tennevet I., Limacher J.-M., Maugard C., Bignon Y.-J., Demange L., Dreyfus H., Cohen-Haguenauer O., Gilbert B., Zattara-Cannoni H., Schrijver L.H., Olsson H., Phillips K.-A., Terry M.B., Goldgar D.E., Kast K., Engel C., Mooij T.M., Adlard J., Barrowdale D., Davidson R., Eeles R., Ellis S., Evans D.G., Frost D., Izatt L., Porteous M.E., and Side L.E.

Abstract

Background: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. Method(s): Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and fullcohort retrospective analyses were performed. Result(s): For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-termpregnancy (BRCA1: both retrospective analyses, P < .001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002). Conclusion(s): Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40-50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-termOCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and nonhormonal contraceptive methods should be discussed.Copyright © The Author(s) 2018.

Published
2018

20. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

Author

Terry, MB, Liao, Y, Kast, K, Antoniou, AC, McDonald, JA, Mooij, TM, Engel, C, Nogues, C, Buecher, B, Mari, V, Moretta-Serra, J, Gladieff, L, Luporsi, E, Barrowdale, D, Frost, D, Henderson, A, Brewer, C, Evans, DG, Eccles, D, Cook, J, Ong, K-R, Izatt, L, Ahmed, M, Morrison, PJ, Dommering, CJ, Oosterwijk, JC, Ausems, MGEM, Kriege, M, Buys, SS, Andrulis, IL, John, EM, Daly, M, Friedlander, M, McLachlan, SA, Osorio, A, Caldes, T, Jakubowska, A, Simard, J, Singer, CF, Tan, Y, Olah, E, Navratilova, M, Foretova, L, Gerdes, A-M, Roos-Blom, M-J, Arver, B, Olsson, H, Schmutzler, RK, Hopper, JL, van Leeuwen, FE, Goldgar, D, Milne, RL, Easton, DF, Rookus, MA, Andrieu, N, Evans, G, Adlard, J, Eeles, R, Davidson, R, Tischkowitz, M, Snape, K, Walker, L, Porteous, M, Donaldson, A, Morrison, P, Eason, J, Rogers, M, Miller, C, Brady, A, Kennedy, MJ, Barwell, J, Gregory, H, Pottinger, C, Murray, A, Angelakos, M, Dite, G, Tsimiklis, H, Breysse, E, Pontois, P, Laborde, L, Stoppa-Lyonnet, D, Gauthier-Villars, M, Caron, O, Fourme-Mouret, E, Fricker, J-P, Lasset, C, Bonadona, V, Fert-Ferrer, S, Berthet, P, Venat-Bouvet, L, Gilbert-Dussardier, B, Faivre, L, Gesta, P, Sobol, H, Eisinger, F, Longy, M, Dugast, C, Coupier, I, Colas, C, Soubrier, F, Pujol, P, Corsini, C, Lortholary, A, Vennin, P, Adenis, C, Tan, DN, Penet, C, Delnatte, C, Tinat, J, Tennevet, I, Limacher, J-M, Maugard, C, Demange, L, Dreyfus, H, Cohen-Haguenauer, O, Leroux, D, Zattara-Cannoni, H, Bera, O, Hogervorst, FBL, Adank, MA, Schmidt, MK, Russell, NS, Jenner, DJ, Collee, JM, van den Ouweland, AMW, Hooning, MJ, Seynaeve, CM, van Deurzen, CHM, Obdeijn, IM, van Asperen, CJ, Devilee, P, Kets, CM, Mensenkamp, AR, Koudijs, MJ, Aalfs, CM, van Engelen, K, Gille, JJP, Gomez-Garcia, EB, Blok, MJ, van der Hout, AH, Mourits, MJ, de Bock, GH, Siesling, S, Verloop, J, van den Belt-Dusebout, AW, Terry, MB, Liao, Y, Kast, K, Antoniou, AC, McDonald, JA, Mooij, TM, Engel, C, Nogues, C, Buecher, B, Mari, V, Moretta-Serra, J, Gladieff, L, Luporsi, E, Barrowdale, D, Frost, D, Henderson, A, Brewer, C, Evans, DG, Eccles, D, Cook, J, Ong, K-R, Izatt, L, Ahmed, M, Morrison, PJ, Dommering, CJ, Oosterwijk, JC, Ausems, MGEM, Kriege, M, Buys, SS, Andrulis, IL, John, EM, Daly, M, Friedlander, M, McLachlan, SA, Osorio, A, Caldes, T, Jakubowska, A, Simard, J, Singer, CF, Tan, Y, Olah, E, Navratilova, M, Foretova, L, Gerdes, A-M, Roos-Blom, M-J, Arver, B, Olsson, H, Schmutzler, RK, Hopper, JL, van Leeuwen, FE, Goldgar, D, Milne, RL, Easton, DF, Rookus, MA, Andrieu, N, Evans, G, Adlard, J, Eeles, R, Davidson, R, Tischkowitz, M, Snape, K, Walker, L, Porteous, M, Donaldson, A, Morrison, P, Eason, J, Rogers, M, Miller, C, Brady, A, Kennedy, MJ, Barwell, J, Gregory, H, Pottinger, C, Murray, A, Angelakos, M, Dite, G, Tsimiklis, H, Breysse, E, Pontois, P, Laborde, L, Stoppa-Lyonnet, D, Gauthier-Villars, M, Caron, O, Fourme-Mouret, E, Fricker, J-P, Lasset, C, Bonadona, V, Fert-Ferrer, S, Berthet, P, Venat-Bouvet, L, Gilbert-Dussardier, B, Faivre, L, Gesta, P, Sobol, H, Eisinger, F, Longy, M, Dugast, C, Coupier, I, Colas, C, Soubrier, F, Pujol, P, Corsini, C, Lortholary, A, Vennin, P, Adenis, C, Tan, DN, Penet, C, Delnatte, C, Tinat, J, Tennevet, I, Limacher, J-M, Maugard, C, Demange, L, Dreyfus, H, Cohen-Haguenauer, O, Leroux, D, Zattara-Cannoni, H, Bera, O, Hogervorst, FBL, Adank, MA, Schmidt, MK, Russell, NS, Jenner, DJ, Collee, JM, van den Ouweland, AMW, Hooning, MJ, Seynaeve, CM, van Deurzen, CHM, Obdeijn, IM, van Asperen, CJ, Devilee, P, Kets, CM, Mensenkamp, AR, Koudijs, MJ, Aalfs, CM, van Engelen, K, Gille, JJP, Gomez-Garcia, EB, Blok, MJ, van der Hout, AH, Mourits, MJ, de Bock, GH, Siesling, S, Verloop, J, and van den Belt-Dusebout, AW

Abstract

BACKGROUND: Full-term pregnancy (FTP) is associated with a reduced breast cancer (BC) risk over time, but women are at increased BC risk in the immediate years following an FTP. No large prospective studies, however, have examined whether the number and timing of pregnancies are associated with BC risk for BRCA1 and BRCA2 mutation carriers. METHODS: Using weighted and time-varying Cox proportional hazards models, we investigated whether reproductive events are associated with BC risk for mutation carriers using a retrospective cohort (5707 BRCA1 and 3525 BRCA2 mutation carriers) and a prospective cohort (2276 BRCA1 and 1610 BRCA2 mutation carriers), separately for each cohort and the combined prospective and retrospective cohort. RESULTS: For BRCA1 mutation carriers, there was no overall association with parity compared with nulliparity (combined hazard ratio [HRc] = 0.99, 95% confidence interval [CI] = 0.83 to 1.18). Relative to being uniparous, an increased number of FTPs was associated with decreased BC risk (HRc = 0.79, 95% CI = 0.69 to 0.91; HRc = 0.70, 95% CI = 0.59 to 0.82; HRc = 0.50, 95% CI = 0.40 to 0.63, for 2, 3, and ≥4 FTPs, respectively, P trend < .0001) and increasing duration of breastfeeding was associated with decreased BC risk (combined cohort P trend = .0003). Relative to being nulliparous, uniparous BRCA1 mutation carriers were at increased BC risk in the prospective analysis (prospective hazard ration [HRp] = 1.69, 95% CI = 1.09 to 2.62). For BRCA2 mutation carriers, being parous was associated with a 30% increase in BC risk (HRc = 1.33, 95% CI = 1.05 to 1.69), and there was no apparent decrease in risk associated with multiparity except for having at least 4 FTPs vs. 1 FTP (HRc = 0.72, 95% CI = 0.54 to 0.98). CONCLUSIONS: These findings suggest differential associations with parity between BRCA1 and BRCA2 mutation carriers with higher risk for uniparous BRCA1 carriers and parous BRCA2 carriers.

Published
2018

26. Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study

Author

Jacquet, E., primary, Lardy-Cleaud, A., additional, Pistilli, B., additional, Cottu, P., additional, Delaloge, S., additional, Debled, M., additional, Vanlemmens, L., additional, Anne-Valérie, G., additional, Leheurteur, M., additional, Laborde, L., additional, Jacot, W., additional, Berchery, D., additional, Coudert, B., additional, Ferrero, J-M., additional, Parent, D., additional, Diéras, V., additional, Velten, M., additional, Courtinard, C., additional, Robain, M., additional, and Bachelot, T., additional

Published
2017
Full Text
View/download PDF

27. Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

Author

Rahal, S., primary, Boher, J M, additional, Extra, J M, additional, Tarpin, C., additional, Charafe-Jauffret, E., additional, Lambaudie, E., additional, Sabatier, R., additional, Thomassin-Piana, J., additional, Tallet, A., additional, Resbeut, M., additional, Houvenaeghel, G., additional, Laborde, L., additional, Bertucci, F., additional, Viens, P., additional, and Gonçalves, A., additional

Published
2015
Full Text
View/download PDF

29. TORE SUPRA Team Mmembers 1988-2008

Author

Abgrall, R., Achard, M.H., Adam, J., Agarici, G., Agostini, E., Airaj, M., Albajar-Vinas, F., Allegretti, L., Allibert, J.P., Alliez, J.C., Allouche, A., Andreoletti, J., Ane, J.M., Angelino, P., Aniel, T., Antar, G., Arcis, N., Argouarch, A., Arnas, C., Arnoux, G., Arslanbekov, R., Artaud, J.F., Asp, E., Assas, S., Atttuel, G., Aymar, R., Azeroual, A., Balme, S., Barana, O., Bareyt, B., Basiuk, V., Basko, M., Bayetti, P., Baylor, L., Beaumont, B., Becherer, R., Becoulet, A., Becoulet, M., Begrambekov, L., Benkadda, S., Benoit, F., Bergeaud, V., Berger-By, G., Berio, S., Bernascolle, P., Bernier, N., Berroukeche, M., Bertrand, B., Bessette, D., Beyer, P., Bibet, P., Bizzaro, J., Blanchard, P., Blum, J., Boddeker, S., Boilson, D., Mardion, G.B., Bonnel, P., Bonnin, X., Boscary, J., Bosia, G., Bottereau, J.M., Bottiglioni, F., Bottollier-Curtet, H., Bouchand, C., Bouligand, G., Bouquey, F., Bourdelle, C., Bregeon, R., Bremond, F., Bremond, S., Breton, C., Breton, M., Brosset, C., Brugnetti, R., Bruneau, J.L., Bucalossi, J., Budny, R.V., Buravand, Y., Bush, C., Bussac, M.N., Cambe, A., Capes, H., Capitain, J.J., Cara, P., Carbonnier, J.L., Carpentier, S., Carrasco, J., Casati, A., Chaibi, O., Chamouard, C., Chantant, M., Chappuis, P., Chatain, D., Chatelier, E., Chatelier, M., Chatenet, J.H., Chen, X.P., Cherigier, L., Chevet, G., Chiarazzo, L., Ciazynski, D., Ciraolo, G., Cismondi, F., Clairet, F., Clary, J., Clement, C., Colas, L., Commaux, N., Corbel, E., Cordier, J.J., Corre, Y., Costanzo, L., Cote, A., Coulon, J.P., Courtois, L., Courtois, X., Couturier, B., Crenn, J.P., Cristofani, P., Crouseilles, N., Czarny, O., Rosa, P.D., Darbos, C., Darmet, G., Davi, M., Daviot, R., De Esch, H., De Gentile, B., De Haas, J.C., De La Cal, E., De Michelis, C., Deck, C., Decker, J., Decool, P., Degond, P., Dejarnac, R., Delchambre, E., Delmas, E., Delpech, L., Demarthe, H., Dentan, M., Depret, G., Deschamps, P., Desgranges, C., Devynck, P., Doceul, L., Dolgetta, N., Doloc, C., Dong, Y., Dore, P., Douai, D., Dougnac, H., Drawin, H.W., Druaux, J., Druetta, M., Dubois, F., Dubois, M., Dubuit, N., Duchateau, J.L., de Wit, T.D., Dufour, E., Dumont, R., Dunand, G., Dupas, L., Duran, Y., Durocher, A., Edery, D., Ekedahl, A., Elbeze, D., Eriksson, L.G., Escande, D., Escarguel, A., Escourbiac, F., Evans, T., Faisse, F., Falchetto, G., Fall, T., Farge, M., Farjon, J.L., Faudot, E., Fazilleau, P., Fedorczak, N., Fenzi-Bonizec, C., Ferron, J.R., Fidone, I., Figarella, C., Fleurence, E., Fleury, I., Fois, M., Forrest, C., Foster, C.A., Fouquet, S., Fourment, C., Fraboulet, D., Francois, P., Franel, B., Frigione, D., Froissard, P., Fubiani, G., Fuchs, V., Fumelli, M., Gagey, B., Galindo, V., Gambier, D., Garampon, L., Garbet, X., Garbil, R., Garcia, J., Gardarein, J.L., Gargiulo, L., Garibaldi, P., Garin, P., Gauthier, E., Geraud, A., Gerbaud, T., Gervais, F., Geynet, M., Ghendrih, P., Gianakon, T., Giannella, R., Gil, C., Girard, J.P., Giruzzi, G., Godbert-Mouret, L., Gomez, P., Goniche, M., Gordeev, A., Granata, G., Grandgirard, V., Gravier, R., Gravil, B., Gregoire, M., Gregoire, S., Grelot, P., Gresillon, D., Grisolia, C., Gros, G., Grosman, A., Grua, P., Guerin, O., Guigon, R., Guilhem, D., Guillerminet, B., Guirlet, R., Guiziou, L., Gunn, J., Hacquin, S., Harris, J., Haste, G., Hatchressian, J.C., Hemsworth, R., Hennequin, P., Hennion, F., Hennion, V., Henry, D., Hernandez, C., Hertout, P., Hess, W., Hesse, M., Heuraux, S., Hillairet, J., Hoang, G.T., Hogan, J., Hong, S.H., Honore, C., Horton, L., Horton, W.W., Houlberg, W.A., Hourtoule, J., Houry, M., Houy, P., How, J., Hron, M., Hutter, T., Huynh, P., Huysmans, G., Idmtal, J., Imbeaux, F., Isler, R., Jaben, C., Jacquinot, J., Jacquot, C., Jager, B., Jaunet, M., Javon, C., Jelea, A., Jequier, F., Jie, Y.X., Jimenez, R., Joffrin, E., Johner, J., Jourd'heuil, L., Y. Journeaux, J, Joyer, P., Ju, M., Jullien, F., Junique, F., Kaye, S.M., Kazarian, F., Khodja, H., Klepper, C., Kocan, M., Koski, J., Krivenski, V., Krylov, A., Kupfer, K., Kuus, H., Labit, B., Laborde, L., Lacroix, B., Ladurelle, L., Lafon, D., Lamaison, V., Laporte, P., Lasalle, J., Latu, G., Laugier, F., Laurent, L., Lausenaz, Y., Laviron, C., Layet, J.M., Le Bris, A., Le Coz, F., Le Niliot, C., Leclert, G., Lecoustey, P., Ledyankinc, A., Leloup, C., Lennholm, M., Leroux, F., Y. Li, Y, Libeyre, P., Linez, F., Lipa, M., Lippmann, S., Litaudon, X., Liu, W.D., Loarer, T., Lott, F., Lotte, P., Lowry, C., Luciani, J.F., Lutjens, H., Luty, J., Lutz, T., Lyraud, C., Maas, A., Macor, A., Madeleine, S., Magaud, P., Maget, P., Magne, R., Mahdavi, A., Mahe, F., Mailloux, J., Mandl, W., Manenc, L., Marandet, Y., Marbach, G., Marechal, J.L., Martin, C., Martin, G., Martin, V., Martinez, A., Martins, J.P., Maschke, E., Masse, L., Masset, R., Massmann, P., Mattioli, M., Mayaux, G., Mayoral, M.L., Mazon, D., McGrath, R., Mercier, C., Meslin, B., Meunier, L., Meyer, O., Michelot, Y., Million, L., Millot, P., Minguella, G., Minot, F., Mioduszewski, P., Misguich, J.H., Miskane, F., Missirlian, M., Mitteau, R., Moerel, F., Mollard, P., Monakhov, I., Moncada, V., Moncel, L., Monier-Garbet, P., Moreau, D., Moreau, F., Moreau, P., Morera, J.P., Moret, J.M., Moulin, B., Moulin, D., Mourgues, F., Moustier, M., Nakach, R., Nannini, M., Nanobashvili, I., Nardon, E., Navarra, P., Nehme, H., Nguyen, C., Nguyen, F., Nicollet, S., Nygren, R., Ogorodnikova, O., Olivain, J., Orlandelli, P., Ottaviani, M., Ouvrier-Buffet, P., Ouyang, Z., Owen, L., Pacella, D., Pain, M., Pamela, J., Pamela, S., Panek, R., Panzarella, A., Paris, R., Parisot, T., Park, S.H., Parlange, F., Parrat, H., Pastor, G., Pastor, P., Pastor, T., Patris, R., Paume, M., Payan, J., Pecquet, A.L., Pegourie, B., Petrov, Y., Petrzilka, V., Peysson, Y., Piat, D., Picchiottino, J.M., Pierre, J., Platz, P., Portafaix, C., Prou, M., Pugno, R., Putchy, L., Qin, C.M., Quallis, L., Quemeneur, A., Quet, P., Rabaglino, E., Raharijaona, J.J., Ramette, J., Ravenel, N., Rax, J.M., Reichle, R., Renard, B., Renner, H., Reuss, J.D., Reux, C., Reverdin, C., Rey, G., Reynaud, P., Riband, P.H., Richou, M., Rigollet, F., Rimini, F., Riquet, D., Rochard, F., Rodriguez, L., Romanelli, M., Romannikov, A., Rosanvallon, S., Roth, J., Rothan, B., Roubin, J.P., Roubin, P., Roupillard, G., Roussel, P., Ruggieri, R., Sabathier, F., Sabbagh, S.A., Sabot, R., Saha, S.K., Saint-Laurent, F., Salasca, S., Salmon, T., Salvador, J., Samaille, F., Samain, A., Santagiustina, A., Saoutic, B., Sarazin, Y., Schild, T., Schlosser, J., Schneider, M., Schneider, K., Schunke, B., Schwander, F., Schwob, J.L., Sebelin, E., Segui, J.L., Seigneur, A., Shepard, T., Shigin, P., Signoret, J., Simoncini, J., Simonet, F., Simonin, A., Sirinelli, A., Sledziewski, Z., Smits, F., Soler, K., Sonato, P.G., Song, S.D., Sonnendrucker, E., Sourd, F., Spitz, P., Spuig, P., Stamm, R., Stephan, Y., Stirling, W., Stockel, J., Stott, P., Sthal, K.S., Surle, F., Svensson, L., Tachon, J., Talvard, M., Tamain, P., Tavian, L., Tena, M., Theis, J.M., Thomas, C.E., Thomas, P., Thonnat, M., Tobin, S., Tokar, M., Tonon, G., Torossian, A., Torre, A., Trainham, R.C., Travere, J.M., Tresset, G., Trier, E., Truc, A., Tsitrone, E., Turck, B., Turco, F., Turlur, S., Uckan, T., Udintsev, V., Urguijo, G., Utzel, N., Vallet, J.C., Valter, J., Van Houtte, D., Van Rompuy, T., Vatry, A., Verga, A., Vermare, L., Vezard, D., Viallet, H., Villecroze, F., Villedieu, E., Villegas, D., Vincent, E., Voitsekovitch, I., von Hellermann, M., Voslamber, D., Voyer, D., Vulliez, K., Wachter, C., Wagner, T., Waller, V., Wang, G., Wang, Z., Watkins, J., Weisse, J., White, R., Wijnands, T., Witrant, E., Worms, J., Xiao, W., Yu, D., Zabeo, L., Zabiego, M., Zani, L., Zhuang, G., Zou, X.L., Zucchi, E., Zunino, K., and Zwingmann, W.

Published
2009

31. 265P - Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study

Author

Jacquet, E., Lardy-Cleaud, A., Pistilli, B., Cottu, P., Delaloge, S., Debled, M., Vanlemmens, L., Anne-Valérie, G., Leheurteur, M., Laborde, L., Jacot, W., Berchery, D., Coudert, B., Ferrero, J-M., Parent, D., Diéras, V., Velten, M., Courtinard, C., Robain, M., and Bachelot, T.

Published
2017
Full Text
View/download PDF

32. [Performance of the Breastfeeding Assessment Score for the prediction of early weaning in France]

Author

Laborde, L., Fulcheri, J., Gelbert-Baudino, N., Schelstraete, C., Mathieu, M., Durand, M., Baudino, F., Vié Le Sage, F., Gothie, I., Roche, F., Devoldere, C., Salinier, C., Gout, J.-P., Plasse, M., Caron, F.-M., François, Patrice, Labarere, José, ThEMAS, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, and Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-CHU Grenoble

Subjects
Adult, Health Knowledge, Attitudes, Practice, Time Factors, MESH: Health Knowledge, Attitudes, Practice, Weaning, MESH: Risk Assessment, Risk Assessment, Interviews as Topic, MESH: Weaning, Humans, Prospective Studies, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, MESH: Humans, MESH: Time Factors, MESH: Infant, Newborn, Infant, Newborn, Infant, MESH: Adult, MESH: ROC Curve, MESH: Interviews as Topic, MESH: Infant, MESH: Prospective Studies, MESH: Patient Satisfaction, MESH: France, Breast Feeding, ROC Curve, Patient Satisfaction, MESH: Breast Feeding, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, France, MESH: Female
Abstract

National audience; BACKGROUND: The Breastfeeding Assessment Score (BAS) was derived to help identify mothers at increased risk of early weaning in United States. Data are currently lacking on the accuracy of the BAS for French mother-infant pairs. OBJECTIVE: To assess the accuracy of the BAS in a French validation cohort. METHODS: We used the original data from a prospective cohort study of 488 mothers who were breastfeeding at discharge in 9 maternity wards in 2005. The outcome measures were assessed using structured follow-up telephone interviews at 4 and 26 weeks. RESULTS: The weaning rate was 3% at 14 days of infant age. The corresponding area under ROC curve was 0.73 [0.60-0.85] and was comparable to that observed in the derivation cohort (0.75). For a cut point of 8 recommended by the authors of the BAS, 43% of mother-infant pairs were categorized at high risk and the weaning rate in this subgroup was 5%. The mother-infant pairs with a score lower than 8 had a shorter median breastfeeding duration (18 versus 20 weeks, P=0.02), were more likely to report breastfeeding difficulties after discharge (63% versus 53%, P=0.03), and were less likely to be "very satisfied" with breastfeeding experience (66% versus 77%, P=0.007). CONCLUSION: The intrinsic properties of the BAS are robust. However, its use would be of limited interest in France because of the relatively low rate of early weaning. Randomized trials are needed before recommending routine use of BAS-based breastfeeding support intervention.

Published
2006
Full Text
View/download PDF

34. New Dynamic-Model Approach for Simultaneous Control of Distributed Magnetic and Kinetic Parameters in the ITER-like JET Plasmas

Author

Moreau, D., Ariola, M., Mazon, D., Ambrosino, G., Cordoliani, V., De Tommasi, G., Felton, R., Laborde, L., Piccolo, F., Pironti, A., Sartori, F., Tala, Tuomas, and Zabeo, L.

Subjects
Physics::Plasma Physics
Abstract

Real-time control of radially distributed parameters was achieved for the first time on JET in 2004, in view of developing integrated control of steady state advanced tokamak scenarios in ITER. The controller was based on the static plasma response only. It was successful in achieving various targets but was found too sensitive to some rapid plasma events. A technique for the experimental identification of a dynamic plasma model has now been developed, taking into account the physical structure and couplings of the transport equations, but making no quantitative assumptions on the transport coefficients or on their dependences. The approach newly implemented aims to use the combination of heating, current drive and poloidal field systems in an optimal way to achieve a set of simultaneous tasks. Theoretical plasma transport analysis has led to the choice of the relevant state variables, and of a set of constraints to be imposed on the corresponding state-space model in order to best reproduce the dynamic response of the plasma profiles to heating power and loop voltage changes. To cope with the high dimensionality of the state space and the large ratio between the various time scales involved, our model identification procedure and controller design make use of a multiple-time-scale approximation and of the theory of singularly perturbed systems. Conventional optimal control is recovered in the limiting case where the ratio of the thermal confinement time to the resistive diffusion time vanishes. Closed-loop simulations of the new controller have been performed in preparation for experiments in 2006, using either the full-order dynamic plasma response or the two-time-scale approximate response. Comparisons show that the reduced-order controller can perform almost as well as the full-order optimal one. Feedforward compensation of some disturbances such as density changes is also included. Finally, the possibility of controlling the plasma boundary flux together with the plasma shape is a new feature to be exploited on JET together with the experimentally identified physics-based plasma model. Simultaneous control of the plasma shape, the magnetic and kinetic plasma profiles and the boundary flux can thus be attempted and will be needed to achieve non-inductively driven advanced tokamak discharges in ITER. The most recent experimental progress on JET is reported.

Published
2006

35. Real time control of plasma profiles at JET

Author

Ariola, M., Laborde, L., Mazon, D., Moreau, D., Gianmaria De Tommasi, M., Ariola, L., Laborde, D., Mazon, D., Moreau, and DE TOMMASI, Gianmaria

Published
2005

36. Development of Integrated Real-Time Control of Internal Transport Barriers in Advanced Operation Scenarios on JET

Author

Moreau, D., Crisanti, F., Laborde, L., Litaudon, X., Mazon, D., Murari, A., Tala, T., Zabeo, L., Albanese, Raffaele, Ariola, M., Gianmaria De Tommasi, Felton, R., Joffrin, E., Lennholm, M., Pericoli Ridolfini, V., Pironti, Alfredo, Riva, M., Tuccillo, A., Baar, M., La Luna, E., Vries, P., Zastrow, K. D., D., Moreau, F., Crisanti, L., Laborde, X., Litaudon, D., Mazon, A., Murari, T., Tala, L., Zabeo, Albanese, Raffaele, M., Ariola, DE TOMMASI, Gianmaria, R., Felton, E., Joffrin, M., Lennholm, V., Pericoli Ridolfini, Pironti, Alfredo, M., Riva, A., Tuccillo, M., de Baar, E., de la Luna, P., de Vrie, and K. D., Zastrow

Published
2004

37. Simultaneous real-time control of the current and pressure profiles in JET: experiments and modelling

Author

Mazon, D., Murari, A., Ariola, M., Laborde, L., Litaudon, X., Moreau, D., Tala, T., Zabeo, L., Albanese, Raffaele, Crisanti, F., Baar, M., La Luna, E., Gianmaria De Tommasi, Vries, P., Felton, R., Joffrin, E., Pericoli Ridolfini, V., Pironti, Alfredo, Tuccillo, A., Corrigan, G., JET EFDA Contributors, D., Mazon, A., Murari, M., Ariola, L., Laborde, X., Litaudon, D., Moreau, T., Tala, L., Zabeo, Albanese, Raffaele, F., Crisanti, M., De Baar, E., De la Luna, DE TOMMASI, Gianmaria, P., De Vrie, R., Felton, E., Joffrin, V., Pericoli Ridolfini, Pironti, Alfredo, A., Tuccillo, G., Corrigan, and JET EFDA, Contributors

Published
2004

39. Integrated scenario in JET using real-time profile control

Author

Joffrin, E., Crisanti, F., Felton, R., Litaudon, X., Mazon, D., Moreau, D., Zabeo, L., Albanese, R., Ariola, M., Alves, D., Barana, O., Basiuk, V., Bécoulet, A., Bécoulet, M., Blum, J., Bolzonnella, T., Bosak, K., Chareau, J. M., Baar, M., La Luna, E., Vries, P., Dumortier, P., Elbeze, D., Farthing, J., Fernandes, H., Fenzi, C., Giannella, R., Guenther, K., Harling, J., Hawkes, N., Hender, T. C., Howell, D. F., Heesterman, P., Imbeaux, F., Innocente, P., Laborde, L., Lloyd, G., Lomas, P. J., Mcdonald, D. C., Mailloux, J., Mantsinen, M., Messiaen, A., Murari, A., Ongena, J., Orsitto, F., Pericoli-Ridolfini, V., Riva, M., Sanchez, J., Filippo sartori, Sauter, O., Sips, A. C. C., Tala, T., Tuccillo, A., Ester, D., Zastrow, K. -D, and Zerbini, M.

Subjects
Nuclear Energy and Engineering, JET, ITER, Condensed Matter Physics
Abstract

The recent development of real-time measurements and control tools in JET has enhanced the reliability and reproducibility of the relevant ITER scenarios. Diagnostics such as charge exchange, interfero-polarimetry, electron cyclotron emission have been upgraded for real-time measurements. In addition, real-time processes like magnetic equilibrium and q profile reconstruction have been developed and applied successfully in real-time q profile control experiments using model based control techniques. Plasma operation and control against magnetohydrodynamic instabilities are also benefiting from these new systems. The experience gained at JET in the field of real-time measurement and control experiments operation constitutes a very useful basis for the future operation of ITER scenarios.

Published
2003

41. A two-time-scale dynamic-model approach for magnetic and kinetic profile control in advanced tokamak scenarios on JET

Author

Moreau, D., Mazon, D., Ariola, M., De Tommasi, G., Laborde, L., Piccolo, F., Sartori, F., Tala, T., Zabeo, L., Boboc, A., Bouvier, E., Brix, M., Brzozowski, Jerzy H., Challis, C. D., Cocilovo, V., Cordoliani, V., Crisanti, F., De la Luna, E., Felton, R., Hawkes, N., King, R., Litaudon, X., Loarer, T., Mailloux, J., Mayoral, M., Nunes, I., Surrey, E., Zimmerman, O., Moreau, D., Mazon, D., Ariola, M., De Tommasi, G., Laborde, L., Piccolo, F., Sartori, F., Tala, T., Zabeo, L., Boboc, A., Bouvier, E., Brix, M., Brzozowski, Jerzy H., Challis, C. D., Cocilovo, V., Cordoliani, V., Crisanti, F., De la Luna, E., Felton, R., Hawkes, N., King, R., Litaudon, X., Loarer, T., Mailloux, J., Mayoral, M., Nunes, I., Surrey, E., and Zimmerman, O.

Abstract

Real-time simultaneous control of several radially distributed magnetic and kinetic plasma parameters is being investigated on JET, in view of developing integrated control of advanced tokamak scenarios. This paper describes the new model-based profile controller which has been implemented during the 2006-2007 experimental campaigns. The controller aims to use the combination of heating and current drive (H&CD) systems-and optionally the poloidal field (PF) system-in an optimal way to regulate the evolution of plasma parameter profiles such as the safety factor, q(x), and gyro-normalized temperature gradient,. rho*(Te)(x). In the first part of the paper, a technique for the experimental identification of a minimal dynamic plasma model is described, taking into account the physical structure and couplings of the transport equations, but making no quantitative assumptions on the transport coefficients or on their dependences. To cope with the high dimensionality of the state space and the large ratio between the time scales involved, the model identification procedure and the controller design both make use of the theory of singularly perturbed systems by means of a two-time-scale approximation. The second part of the paper provides the theoretical basis for the controller design. The profile controller is articulated around two composite feedback loops operating on the magnetic and kinetic time scales, respectively, and supplemented by a feedforward compensation of density variations. For any chosen set of target profiles, the closest self-consistent state achievable with the available actuators is uniquely defined. It is reached, with no steady state offset, through a near-optimal, QC 20100525

Published
2008
Full Text
View/download PDF

43. Non-inductive current drive and transport in high βN plasmas in JET

Author

Voitsekhovitch, I., primary, Alper, B., additional, Brix, M., additional, Budny, R.V., additional, Buratti, P., additional, Challis, C.D., additional, Ferron, J., additional, Giroud, C., additional, Joffrin, E., additional, Laborde, L., additional, Luce, T.C., additional, McCune, D., additional, Menard, J., additional, Murakami, M., additional, and Park, J.M., additional

Published
2009
Full Text
View/download PDF

44. Integrated plasma controls for steady state scenarios

Author

Joffrin, E., primary, Barana, O., additional, Mazon, D., additional, Moreau, P., additional, Turco, F., additional, Artaud, J.F., additional, Basiuk, V., additional, Bourdelle, C., additional, Brémond, S., additional, Bucalossi, J., additional, Clairet, F., additional, Colas, L., additional, Corre, Y., additional, Dumont, R., additional, Ekedahl, A., additional, Giruzzi, G., additional, Goniche, M., additional, Imbeaux, F., additional, Kazarian, F., additional, Laborde, L., additional, Monier-Garbet, P., additional, Maget, P., additional, Pégourié, B., additional, Peysson, Y., additional, Rimini, F., additional, Saint-Laurent, F., additional, and Tsitrone, E., additional

Published
2007
Full Text
View/download PDF

47. Probing Internal Transport Barriers with Heat Pulses in JET

Author

Mantica, P., primary, Van Eester, D., additional, Garbet, X., additional, Imbeaux, F., additional, Laborde, L., additional, Mantsinen, M., additional, Marinoni, A., additional, Mazon, D., additional, Moreau, D., additional, Hawkes, N., additional, Joffrin, E., additional, Kiptily, V., additional, Pinches, S., additional, Salmi, A., additional, Sharapov, S., additional, Thyagaraja, A., additional, Voitsekhovitch, I., additional, de Vries, P., additional, and Zastrow, K.-D., additional

Published
2006
Full Text
View/download PDF

49. Development of real-time diagnostics and feedback algorithms for JET in view of the next step

Author

Murari, A, primary, Joffrin, E, additional, Felton, R, additional, Mazon, D, additional, Zabeo, L, additional, Albanese, R, additional, Arena, P, additional, Ambrosino, G, additional, Ariola, M, additional, Barana, O, additional, Bruno, M, additional, Laborde, L, additional, Moreau, D, additional, Piccolo, F, additional, Sartori, F, additional, Crisanti, F, additional, Luna, E de la, additional, Sanchez, J, additional, and Contributors, EFDA-JET, additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results